Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects.

  

Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial

Hamidreza Baghani Aval, Zeinab Ameli, Mojtaba Ameli

Urologia Journal.2018; 85(2): 51.     CrossRef

Effets des inhibiteurs de la phosphodiestérase de type 5 sur les symptômes du bas appareil urinaire associés à une hypertrophie bénigne de la prostate

F. Giuliano, M. Rouprêt, G. Doridot, A. de la Taille

Progrès en Urologie.2013; 23(5): 283.     CrossRef

BPH/LUTS and ED: Common Pharmacological Pathways for a Common Treatment

Ferdinando Fusco, Gianluca D'Anzeo, Aurelio Sessa, Gianna Pace, Andrea Rossi, Marco Capece, Roberta d'Emmanuele di Villa Bianca

The Journal of Sexual Medicine.2013; 10(10): 2382.     CrossRef

Phosphodiesterase-5 Expression and Function in the Lower Urinary Tract: A Critical Review

Ching-Shwun Lin, Maarten Albersen, Zhongcheng Xin, Mikio Namiki, Dieter Muller, Tom F. Lue

Urology.2013; 81(3): 480.     CrossRef

Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication

Ali Hamidi Madani, Amin Afsharimoghaddam, Ali Roushani, Alireza Farzan, Ahmad Asadollahzade, Maryam Shakiba

International braz j urol.2012; 38(1): 33.     CrossRef

Phosphodiesterase Type 5 Inhibitors in the Management of Non-neurogenic Male Lower Urinary Tract Symptoms: Critical Analysis of Current Evidence

Juan I. Martínez-Salamanca, Joaquin Carballido, Ian Eardley, Francois Giuliano, Christian Gratzke, Raymond Rosen, Andrea Salonia, Christian Stief

European Urology.2011; 60(3): 527.     CrossRef